This trial is no longer recruiting

Recruitment for this study has ended, so applications are closed. You can still read the trial details, or browse similar trials that are currently recruiting.

Not recruiting

Phase 3

BDA with HFOA Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Sponsor:

AstraZeneca

Code:

NCT06502366

Conditions

Asthma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BDA MDI HFO 160/180 μg

BDA MDI HFA 160/180 μg

Placebo MDI HFA

Study Details

Brief summary:

The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed replacement propellant HFO compared with BDA delivered using the currently approved propellant HFA in participants with asthma.

Conditions

Asthma

Study ID

NCT06502366

Start date

Jul 22, 2024

Status verified date

Dec, 2025

Completion date

Mar 3, 2026

Anticipated

Primary completion date

Mar 3, 2026

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Participant must be ≥ 18 years of age at the time of signing the ICF.
Participants who have physician diagnosed asthma as defined by GINA for at least 12 months prior to Visit 1.
Eligible participants are on either a) no daily inhaled maintenance therapy or b) daily inhaled maintenance therapy with low-dose ICS or low-dose ICS-LABA. Participants who are on low-dose ICS maintenance therapy are required to be stable on therapy for a minimum of 3 months prior to Visit 1; participants using low-dose ICSLABA maintenance regimens are required to be stable on therapy for a minimum of 6 months prior to Visit 1.
Participants with a pre-bronchodilator FEV1 of ≥ 60% and < 90% predicted normal at Visit 1 or Visit 1a.
Participants with a pre-dose FEV1 of ≥ 60% and < 90% predicted normal at Visit 2 that is within ± 20% of their Visit 1 pre-bronchodilator FEV1.
Participants who demonstrate bronchodilator responsiveness defined as a > 12% and > 200 mL increase in FEV1 relative to baseline following administration of study provided SABA at Visit 1 or Visit 1a.
Participants able to demonstrate acceptable spirometry performance as defined by the acceptability and repeatability criteria in the ATS/ERS Standardization of Spirometry 2019 update
Participants who are willing and, in the opinion of the investigator, able to adjust current asthma therapy, as required by the protocol.
Participants with a body mass index < 40 kg/m2.
Females must not be of childbearing potential or, if of childbearing potential, using a form of birth control

Exclusion Criteria:

Confirmed or suspected diagnosis of COPD or clinically significant non-asthma airway/lung disease.
Systemic corticosteroid use (eg, prednisone for 3 or more days or a single depo-injectable dose of corticosteroids) for any respiratory, immune, or allergy-attributed disease within 6 months prior to Visit 1.
An upper respiratory infection requiring antibiotic treatment that is not resolved within 7 days prior to Visit 1.
A lower respiratory infection in the 4 weeks prior to Visit 1.
Life-threatening asthma defined as any history of significant asthma episode(s) requiring admission to an intensive care unit, positive pressure ventilation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s) within 5 years of Visit 1.
Hospitalization due to asthma within 12 months or systemic corticosteroid usage (eg, prednisone for 3 or more days or a single depo-injectable dose of corticosteroids) for asthma within 6 months prior to Visit 1.
A severe asthma exacerbation during the run-in period
An ePRO device alert during the run-in period with investigator-confirmed worsening asthma symptoms
Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular (eg, congestive heart failure, known aortic aneurysm, clinically significant cardiac arrhythmia, coronary heart disease), hepatic, renal, hematological, neuropsychological, endocrine (eg, uncontrolled diabetes mellitus, uncontrolled thyroid disorder, Addison's disease, Cushing's syndrome), or gastrointestinal (eg, poorly controlled peptic ulcer, gastroesophageal reflux disease) disorders. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the participant at risk through study participation or that could affect the efficacy or safety analyses if the disease/condition exacerbated during the study.
Unresectable cancer that has not been in complete remission for at least 5 years prior to Visit 1
Hospitalization for psychiatric disorder or attempted suicide within 1 year of Visit 1.
Known history of drug or alcohol abuse within 12 months of Visit 1 or known abuse at any time during the study.

Study Design

Enrollment

398 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: BDA MDI HFO

160/180 µg Budesonide/albuterol pressurized inhalation suspension, HFO

active comparator: BDA MDI HFA

160/180 µg Budesonide/albuterol pressurized inhalation suspension, HFA

placebo comparator: Placebo MDI HFA

Placebo pressurized inhalation suspension, HFA

Interventions

BDA MDI HFO 160/180 μg

Budesonide/albuterol pressurized inhalation suspension, HFO

BDA MDI HFA 160/180 μg

Budesonide/albuterol pressurized inhalation suspension, HFA

Placebo MDI HFA

Placebo pressurized inhalation suspension, HFA

Primary outcome measure

Change from baseline in peak FEV1 in 0-60 minutes after dosing at Day 29 [ Time Frame: Change from baseline at Day 29 ]
Change from baseline in peak FEV1 in 0-60 minutes after dosing at Day 29 [ Time Frame: Change from baseline at Day 29 ]

Central Contacts and Locations

Central contacts

AstraZeneca Clinical Study Information Center

1-877-240-9479 information.center@astrazeneca.com

Locations

Research Site

Recruiting

Mobile, Alabama, United States, 36608

Research Site

Recruiting

Phoenix, Arizona, United States, 85018

Research Site

Recruiting

Encinitas, California, United States, 92024

Research Site

Recruiting

Fullerton, California, United States, 92835

Research Site

Recruiting

Gardena, California, United States, 90247

Research Site

Recruiting

Huntington Beach, California, United States, 92647

Research Site

Recruiting

La Mesa, California, United States, 91942

Research Site

Recruiting

Los Angeles, California, United States, 90025

Research Site

Recruiting

Los Angeles, California, United States, 90048

Research Site

Recruiting

Sacramento, California, United States, 95821

Research Site

Recruiting

San Diego, California, United States, 92123

Research Site

Recruiting

San Jose, California, United States, 95117

Research Site

Recruiting

Stockton, California, United States, 95207

Research Site

Recruiting

Wheat Ridge, Colorado, United States, 80033

Research Site

Recruiting

Washington D.C., District of Columbia, United States, 20016

Research Site

Recruiting

Boynton Beach, Florida, United States, 33435

Research Site

Recruiting

Tampa, Florida, United States, 33607

Research Site

Recruiting

Atlanta, Georgia, United States, 30328

Research Site

Recruiting

Savannah, Georgia, United States, 31406

Research Site

Recruiting

Meridian, Idaho, United States, 83646

Research Site

Recruiting

River Forest, Illinois, United States, 60305

Research Site

Recruiting

Evansville, Indiana, United States, 47715

Research Site

Recruiting

Valparaiso, Indiana, United States, 46383

Research Site

Recruiting

Sioux City, Iowa, United States, 51106

Research Site

Recruiting

Louisville, Kentucky, United States, 40217

Research Site

Recruiting

Lafayette, Louisiana, United States, 70508

Research Site

Recruiting

New Orleans, Louisiana, United States, 70119

Research Site

Recruiting

White Marsh, Maryland, United States, 21162

Research Site

Recruiting

Flint, Michigan, United States, 48504

Research Site

Recruiting

Columbia, Missouri, United States, 65203

Research Site

Recruiting

St Louis, Missouri, United States, 63141

Research Site

Recruiting

New York, New York, United States, 10036

Research Site

Recruiting

Watertown, New York, United States, 13601

Research Site

Recruiting

Raleigh, North Carolina, United States, 27607

Research Site

Recruiting

Cincinnati, Ohio, United States, 45236

Research Site

Recruiting

Oklahoma City, Oklahoma, United States, 73120

Research Site

Recruiting

Tulsa, Oklahoma, United States, 74136

Research Site

Recruiting

Medford, Oregon, United States, 97504

Research Site

Recruiting

Portland, Oregon, United States, 97202

Research Site

Recruiting

Scottdale, Pennsylvania, United States, 15683

Research Site

Recruiting

North Charleston, South Carolina, United States, 29420

Research Site

Recruiting

Dallas, Texas, United States, 75231

Research Site

Recruiting

DeSoto, Texas, United States, 75115

Research Site

Recruiting

El Paso, Texas, United States, 79924

Research Site

Recruiting

Kingwood, Texas, United States, 77339

Research Site

Recruiting

Pearland, Texas, United States, 77584

Research Site

Recruiting

San Antonio, Texas, United States, 78258

Research Site

Recruiting

Victoria, Texas, United States, 77901

Research Site

Recruiting

West Jordan, Utah, United States, 84088

Research Site

Recruiting

Burke, Virginia, United States, 22015

Research Site

Recruiting

Portsmouth, Virginia, United States, 23703

Research Site

Recruiting

Spokane, Washington, United States, 99218

Research Site

Recruiting

Milwaukee, Wisconsin, United States, 53228

More Information

Sponsor

AstraZeneca

Last update posted

Dec 15, 2025

Last verified

Dec, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-16. This information was provided to ClinicalTrials.gov by AstraZeneca on 2025-12-15.